Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Recruiting · NCT05919108 · Registry updated 2026-08-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | Carcinoma, Lobular, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast disorder, breast neoplasm, carcinoma, epithelial neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-08-19 | NCT05919108 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
| Puma Biotechnology, Inc. | 11 |
| Vanderbilt-Ingram Cancer Center | 42 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baylor College of Medicine | Houston | United States | 306 |
| Emory University/ Winship Cancer Institute | Atlanta | United States | 1 |
| University of Pittsburgh Medical Center | Pittsburgh | United States | 127 |
| University of Texas, Southwestern | Dallas | United States | 5 |
| Vanderbilt University/Ingram Cancer Center | Nashville | United States | 12 |